key: cord-0947564-eywlytx4 authors: Lim, Jihe; Lee, Seun Ah; Khil, Eun Kyung; Byeon, Sun-Ju; Kang, Hee Joon; Choi, Jung-Ah title: COVID-19 Vaccine-Related Axillary Lymphadenopathy in Breast Cancer Patients: Case Series with a Review of Literature date: 2021-10-26 journal: Semin Oncol DOI: 10.1053/j.seminoncol.2021.10.002 sha: c349586b26cfbae5b7aafb305904e5c2542b22fe doc_id: 947564 cord_uid: eywlytx4 Purpose – Lymphadenopathy (LAP) after COVID-19 vaccination in patients with a diagnosis of cancer has been challenging. We analyzed imaging and clinical features from early cases of axillary LAP in six COVID-19 vaccine recipients with a history of breast cancer. Method – Among the patients with a history of breast cancer and recent COVID-19 vaccine administration, six patients who showed isolated axillary LAP were gathered. Radiologic features were reviewed from breast ultrasound, chest computed tomography, and breast magnetic resonance imaging. Clinical and pathological information were obtained for analysis. Results – The interval between ultrasound detection of LAP and last COVID-19 vaccine administration ranged from 14 to 28 days (mean 21.67 days). Round shape of the lymph node and irregular cortex were noted in two and zero cases, respectively. Mean maximum cortical thickness, length to width ratio and interval aggravation in maximum cortical thickening were 4.2 mm, 1.34 and 2.81-fold with cut-off value of 3 mm, 1.5, 2.0-fold, respectively. Conclusion – We observed axillary LAP ipsilateral to a recent vaccine administration persisting longer than what the Centers for Disease Control and Prevention announced. In our patients, COVID-19 vaccine related LAP tended to show increased cortical thickness without cortical irregularity. Oncologist as well as radiologist should be familiar with the fact that COVID-19 vaccines, regardless of vaccine type or dosage, can frequently cause ipsilateral axillary LAP, showing some suspicious features more often than others, and can persist longer than anticipated so that both over- and underdiagnosis can be avoided. We report our observations in six patients and provide an exhaustive review of the published literature Since the beginning of their administration, various reactions and adverse effects of the COVID-19 vaccines have been reported and shared world-wide. [1] [2] [3] [4] [5] [6] [7] While vaccine related lymphadenopathy (LAP) with other vaccines is rare with a few published articles on H1N1 Influenza, human papillomavirus (HPV), smallpox, Bacille Calmette-Guerin (BCG), and measles vaccines, [8] [9] [10] [11] [12] [13] [14] reports of regional LAP in COVID-19 vaccine recipients are gradually increasing along with the rollout of mass COVID-19 vaccination across the world. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Isolated unilateral axillary LAP can be alarming especially in patients with a history of breast cancer. 35, 36 We present six challenging cases of COVID-19 vaccine related axillary LAP in patients with a history of breast cancer. Prior to the routine imaging studies, four patients had received their first dose of the Oxford/AstraZeneca (AZD1222) adenovirus vector COVID-19 vaccine (Vaxzevria), one patient had received her second dose of the Pfizer-BioNTech (BNT 162b2) mRNA COVID-19 vaccine, and one patient had cross-inoculation receiving Vaxzevria first and Pfizer-BioNTech COVID-19 second. Six patients with history of breast cancer underwent one or more imaging studies including breast ultrasound (US) with linear transducer (iU22, Philips Medical System, Bothell, WA, USA), chest computed tomography (CT) with contrast enhancement (Biograph64, Siemens, Erlangen, Germany) and breast magnetic resonance imaging (MRI) with contrast enhancement (MAGNETOM Skyra, Siemens Healthineers, Erlangen, Germany) for follow up or surveillance purposes. Maximum cortical thickness (MCT) of axillary lymph node (LN) was measured from its maximal thickness perpendicular to the inner cortical border on US. Length to width (L/W) ratio was measured on a plane revealing the longest diameter of the targeted LN on CT and MRI. Interval change in maximum cortical thickening (IMCT) was compared with the last follow up exam on CT and MRI. MCT, L/W ratio and IMCT elicited from the measurements of first and second largest LN if multiple and mean value was calculated in each image modality. Higher number was derived among CT and MRI measurement results for IMCT and lower number for L/W ratio to meet the cut-off value. The cut-of values used for MCT, L/W ratio and IMCT are 3 mm or more (≥3 mm), less than 1.5 (<1.5 mm) and more than doubling (≥2 times), respectively. 37, 38 Other imaging features such as shape, marginal irregularity, anatomic location and multiplicity of axillary LAP were included for analysis. 39 Patient information on age, sex, axillary symptom and sign was obtained from the electronic medical record of our facility or asked directly of the patient when performing US by the first author of this article. Prior breast cancer characteristics such as cancer type, subtype, TNM stage, and tumor location was obtained from prior pathologic report or official records from the referring hospital. Date, type and site of COVID-19 vaccine administration were questioned before and after the imaging study to support interpretation and management. A 61-year-old woman with a history of right breast cancer with ipsilateral axillary LN metastasis underwent breast conserving surgery (BCS) with axillary dissection followed by adjuvant chemotherapy and radiation therapy. The cancer type was estrogen-receptor (ER)negative, progesterone-receptor (PR)-negative and human epidermal growth factor receptor 2 (HER2)-positive invasive ductal carcinoma (IDC) with medullary features and she received trastuzumab therapy. Unexpectedly in a routine 5-year follow up multiple, enlarged lymph nodes were observed in left axillary region on imaging studies. She didn"t have any other suspicious findings in both breasts and right axilla on US, mammography, CT and MRI. She was asked about recent vaccination history before further intervention, and she reported she had received her first dose of Vaxzevria in the left arm 16 days before the imaging studies. We presumed this new left axillary LAP was most likely due to the vaccine, but the patient desired a definitive answer urgently. US guided 14-gauge gun biopsy was performed and the pathology reported benign hyperplasia. (Figure 1 ) A 75-year-old woman with a history of ER-positive, PR-positive, and HER2-negative IDC with mucin production in her right breast without axillary LN metastases received proper treatment and came back to the hospital for her 2.5-year follow up. Multiple enlarged, round and coffee bean-shaped lymph nodes were detected in levels I and II of the left axilla, showing a MCT of 5.38 mm on US and mean L/W ratio less than 1.5 on CT and MRI. IMCT had more than doubled compared with last imaging studies. She reported having had her second dose of the Pfizer-BioNTech COVID-19 vaccine 14 days prior to the hospital visit and the pathologic confirmation was reactive hyperplasia. A 71-year-old woman with a history of ER-positive, PR-positive, and HER2-positive IDC in the right breast with no axillary metastasis had 8-year surveillance exams after proper treatment. A 61-year-old woman with history of ER-positive, PR-negative and HER2-negative IDC of the left breast with ipsilateral axillary LN metastasis had BCS with axillary dissection followed by radiation therapy and chemotherapy. New right axillary LAP was detected on 3-year follow up imaging studies and she reported having received her first dose of Vaxzevria in the right arm 19 days prior to the hospital visit. She agreed on a 3-month follow up with axillary US. All six cases presented with asymptomatic unilateral axillary LAP contralateral to their prior breast cancer and ipsilateral to the recent COVID-19 vaccine injection. The age of six patients ranged from 61 to 75 years old (median 68 years old, mean 67.2 years old) and none of the patients complained about symptoms or signs concerning for axillary LAP before the routine examinations. Five of the six patients had a prior history of IDC with one case of DCIS; ER, PR and HER2 status varied. TNM stages of the breast cancers in this study group were early in five but advanced for case 5 who presented with clinical stage T2N2 disease but experienced a complete response to NAC with ypT0N0 staging at the time of surgery. On pathologic examination all tumors were smaller than 2 cm in the longest dimension and three cases had ipsilateral axillary LN metastasis before treatment but none of the cases had contralateral axillary LN metastasis. In radiologic feature analysis, round shape of the LN was noted in two cases but irregular cortical margins were not detected in any of the cases. Mean MCT, L/W ratio and aggravated IMCT ranged from 3.0 mm to 6.4 mm, 1.6 to 2.09 and 1.7 to 3.75 times, respectively (mean values were 4.2 mm, 1.34, and 2.81 times, respectively). All, five of six and five of six tumors met the cut-off value of MCT, L/W ratio and IMCT aggravation, respectively. (Table 1 ) Publications: As of early October 2021, over 80 articles are accessible on-line or in-print focusing on COVID-19 vaccine-related LAP. Over 60% of them are case reports or case series reporting less than 10 cases each. Less than 20 original studies were published from January to early October 2021 analyzing clinical and radiological features of LAP. Around one dozen articles review the phenomenon and updated clinical guidelines. 15, 17, 19, 20, [22] [23] [24] [25] [26] [27] [28] [29] [31] [32] [33] [34] 38, While more than half of the literature was published in radiology journals, the first authors varied from oncologists and medical physician to pathologists and radiologists. Some cases of LAP were symptomatic but most cases in large groups were asymptomatic with LAP incidentally recognized during cancer workup or in screening settings. Most studies reported on patients in the USA, probably owing to different socio-economical environments for the vaccination. (Table 2 ) Incidence: Moderna COVID-19 (mRNA-1273) vaccine related clinical LAP was reported up to 16%. 91 Barda 43 Reported imaging prevalence of COVID-19 vaccine related LAP with or without clinical symptom varies from 3% (23 out of 750 patients with or without malignancy on mammography) 72 to 9% (21 out of 232 patients with history of thoracic malignancy on CT) 67 . Reported nuclear imaging prevalence of COVID-19 vaccine related LAP is higher up to 66% (180 out of 274 with underlying oncologic condition). 68 As evidence of COVID-19 vaccine related benign LAP accumulates, many authors are suggesting that the incidence of subclinical LAP will rise on screening or diagnostic imaging studies along with world-wide mass rollout of COVID-19 vaccines. 55 The median number of increased nodes was 4 (range: 1-10). The median time to the post-vaccine scan revealing lymphadenopathy was 1.7 weeks (range: -2.9 to 6.6) from the second dose. 67 Cocco et al. analyzed US features of 24 cases with vaccine related LAP. The median size was 0.9 cm ± 0.19 on US and the number of nodes was less than 3 in 83.3%. The prevalent morphology was ovular in 18 patients (75%) and round in six patients (25%). The prevalent cortex-hilum pattern was asymmetric cortex with hilum evidence (9, 37.5%), followed by the absence of hilum (8, 33.3%) and symmetric cortex with hilum evidence (7, 29.2%). Elastosonography patterns were like the surrounding tissue in 15 cases (71.4%) and prevalently hard in nine cases (28.6%). 49 While not many articles describe findings of mammography compared with other modalities, The challenge lies when a patient with a history of a malignancy with a tendency to involve axillary LNs, such as breast cancer, melanoma and lymphoma, presents with isolated axillary LAP after a COVID-19 vaccine injection. There are over 160,000 women currently living with metastatic breast cancer in the United States and an even larger number world-wide. 99 Cohen et al. reported that the greatest difficulty in the differential diagnosis between vaccine associated hypermetabolic LAP and malignant LAP were in patients with either breast cancer or lymphoma. 92 Well-known radiologic features of pathologic LAP include cortical thickening more than 3 mm, marked hypoechoic cortices, round shape, loss of fatty hilum, cortical irregularity, L/W ratio less than 1.5 and interval cortical thickening aggravation greater than two times in comparison with prior imaging study. 39, 41 Furthermore, there can be overlapping "worrisome" features in vaccine-related self-limited LAP such as a round shape, irregular cortex and stiffness with an aggravated IMCT and L/W ratio < 1.5 as seen in our study. 49 Round shape with loss of hilum and irregular margin of LN were less frequently encountered in our study group. Given that even a little change in the shape or size of axillary LNs in follow up or surveillance imaging studies can be of concern to both clinicians and radiologists, common as well as uncommon findings and overlapping malignant features as well as typically benign features of vaccine related LAP should be shared and recognized. Practical strategy for injection, medical recording and more: The European Society of Breast Imaging (EUSOBI) recently announced ten proposals for vaccine related axillary LAP, reinforcing prior SBI statements and assembling the published literature. 89 These recommendations include vaccine injection in the cancer-free arm, vaccination data collection prior to breast imaging referrals and routine imaging at least 12 weeks after the last vaccine dose. They emphasized managing lymphadenopathy, considering the time frame from vaccination and overall nodal metastatic risk in patients with breast cancer, and a multidisciplinary team approach for complex and unclear cases. Our six patients received vaccine injections in the cancer-free arm, but still three patients proceeded to invasive pathologic confirmation. In correlation with the result of our study we agree on the need for collecting medical records on the COVID-19 vaccination status of the patient in effort to reduce false positive biopsies. 16, 29 In our institution, we started have begun to obtain information that includes the date, dose, type and location of the COVID-19 vaccine injection from all visiting or referred patients before performing breast imaging studies. Owing to accumulation of experience on COVID-19 vaccine-related axillary LAP, an increasing number of authors advocate a conservative short term follow up over prompt invasive intervention. 15, 16, 19, 21, [25] [26] [27] [28] [29] [31] [32] [33] [34] We also have been recommending Limitations: This is retrospective review of a limited number of patients with a history of earlystage breast cancer and with COVID-19 vaccine-related LAP in single institution. Further experience in a larger group will allow for safer and more discrete guidelines in interpreting and managing isolated LAP in patients with cancer. Oncologist as well as radiologist should be familiar with the fact that regardless of type or vaccine dose, COVID-19 vaccines can frequently cause ipsilateral axillary LAP, showing some suspicious features more often than others, and lasting longer than the anticipated period of time so that both over-and underdiagnosis can be avoided. And this awareness should receive special consideration in patients with a diagnosis of breast cancer. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Immunological considerations for COVID-19 vaccine strategies Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine. 2021 Adverse events associated with smallpox vaccination in the United States Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine Live, attenuated measles virus vaccine. Inguinal lymphadenopathy complicating administration Tuberculous lymphadenitis as a cause of persistent cervical lymphadenopathy in children from a tuberculosis-endemic area Adenopathy Following COVID-19 Vaccination Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging Axillary Lymphadenopathy After mRNA COVID-19 Vaccination COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT COVID-19 vaccination induced axillary nodal uptake on [18F]FDG PET/CT COVID-19 Vaccination-Related Uptake on FDG PET/CT: An Emerging Dilemma and Suggestions for Management COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination FDG Avid Axillary Lymph Nodes After COVID-19 Vaccination FDG PET Findings Post-COVID Vaccinations: Signs of the Times? Lymphadenopathy Associated With the COVID-19 Vaccine Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic Patients Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel Supraclavicular lymphadenopathy following COVID-19 vaccination: an increasing presentation to the two-week wait neck lump clinic? Unilateral axillary Adenopathy in the setting of COVID-19 vaccine Unilateral Axillary Lymphadenopathy After Coronavirus Disease (COVID-19) Vaccination Unilateral axillary lymphadenopathy following COVID-19 vaccination: A case report and imaging findings Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties A practical approach to imaging the axilla Unilateral axillary adenopathy with unremarkable breast imagingdifferential diagnoses Preoperative ultrasound of axillary lymph nodes in patients with breast cancer Imaging of axillary lymph nodes Retrospective preoperative assessment of the axillary lymph nodes in patients with breast cancer and literature review Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination Cervical lymphadenopathy following coronavirus disease 2019 vaccine: clinical characteristics and implications for head and neck cancer services COVID-19 Vaccination Manifesting as Unilateral Lymphadenopathies Detected by 18F-Choline PET/CT Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting FDG-Avid Ipsilateral Iliac and Inguinal Lymphadenopathy After COVID-19 Vaccination With Thigh Injection DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination Unilateral axillary adenopathy following COVID-19 vaccination: a multimodality pictorial illustration and review of current guidelines Unilateral lymphadenopathy after COVID-19 vaccination A Case of Cervical Lymphadenopathy After Vaccination Against COVID-19 Lymphadenopathy after the Anti-COVID-19 Vaccine: Multiparametric Ultrasound Findings Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy Interference of COVID-19 Vaccination With PET/CT Leads to Unnecessary Additional Imaging in a Patient With Metastatic Cutaneous Melanoma-Case Report Ultrasound and shearwave elastography patterns of COVID-19 mRNA vaccine-related axillary, supra and subclavicular lymphadenopathy Imaging of COVID-19 Vaccination at FDG PET/CT COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management Regional lymphadenopathy following COVID-19 vaccination: considerations for primary care management Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings Fine needle aspiration in COVID-19 vaccine-associated lymphadenopathy Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up using ultrasonography DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT COVID-19 vaccination and low cervical lymphadenopathy in the two week neck lump clinic -a follow up audit COVID-19 Vaccination-Associated Axillary Adenopathy: Imaging Findings and Follow-Up Recommendations in 23 Women Features of Systemic Immune Response From COVID-19 Vaccination on 18F-FDG PET/CT Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT-not only an FDG finding Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics Lessons learned from post-COVID-19 vaccination PET/CT studies Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma Cortés Romera M. 68Ga-DOTATOCavid lymphadenopathies induced from COVID-19 mRNA vaccination Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine Case report of lymph node activation mimicking cancer progression: A false positive F(18) FDG PET CT after COVID-19 vaccination Frequency and Characteristics of Nodal and Deltoid FDG and (11)C-Choline Uptake on PET Performed After COVID-19 Vaccination COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan 18)F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact Reactive Axillary Lymphadenopathy to COVID-19 Vaccination on (18)F-FDG PET/CT Hypermetabolic lymphadenopathy on positron emission tomography scan following COVID-19 vaccination: A mimicker of disease progression in Hodgkin lymphoma Supraclavicular and Axillary Lymphadenopathy Induced by COVID-19 Vaccination on 18F-Fluorthanatrace, 68Ga-DOTATATE, and 18F-Fluciclovine PET/CT COVID-19 post-vaccination lymphadenopathy: Report of cytological findings from fine needle aspiration biopsy Lymphadenopathy with florid lymphoid and Langerhans cell hyperplasia and hemophagocytosis mimicking lymphoma after COVID-19 mRNA vaccination Post COVID-19 vaccine adenopathy: first Brazilian report The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination Medical imaging in times of pandemic: focus on the cornerstones of successful imaging Managing the Risk of Delayed Breast Cancer Screening Versus COVID-19 Vaccination Associated Axillary Lymphadenopathy COVID-19 vaccination and breast cancer surgery timing Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI) COVID-19 Vaccination-Related Lymphadenopathy: What To Be Aware Of The Moderna COVID-19 Vaccine"s Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation COVID-19 vaccine-related unilateral axillary lymphadenopathy: Pattern on screening breast MRI allowing for a benign assessment Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination Mammographic and sonographic findings in the breast and axillary tail following a COVID-19 vaccine The Canadian Society of Breast Imaging Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination -Update Committee SoBIPCaD. SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States Vaxzevri a 22 19 14 28 21 26 Side of vaccination/axillar y LAP/prior breast cancer L/L/R L/L/R R/R/L L/L/R L/L/R R/R/L 3072 † † * Only articles with clear demonstration of the cases and full-text accessibility were included between January 1 and October 1, 2021 ** Number of cases described as COVID-19 related lymphadenopathy in the article, not total number or enrolled number of the study in each literature. *** Cases from articles describing the vaccine only as "mRNA COVID-19 vaccine" without specification.† Cases from articles describing the vaccine only as "COVID-19 vaccine" without specification. ‡ Including supraclavicular, infraclavicular and sub-clavicular area as mentioned in the articles. § Cases showing contralateral axillary lymphadenopathy or any other area of the body except ipsilateral axilla, peri-clavicular and cervical area to vaccine injection site. 65, 71, 94 ¶ Cases from one article describing lymphadenopathy only as "lymphadenopathy" without anatomical location. 43 ‖ Considered as local reaction given the case had COVID-19 vaccine injection on thigh muscle instead of usual deltoid musle. 44 † † All the cases without clear number and corresponding localization of the lymphadenopathy were excluded from this summary table.